Drug Profile
Research programme: radiosensitising and radioprotecting compounds - Radiation Control Technologies
Alternative Names: RCT-1938Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Institutes of Health (USA)
- Developer Radiation Control Technologies
- Class
- Mechanism of Action Apoptosis inhibitors; CD47 antigen inhibitors; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute radiation syndrome; Head and neck cancer; Radiation injuries
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Head-and-neck-cancer(Adjuvant therapy) in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Radiation injuries (Prevention) in USA